Verified Nov 2026
Other
·

Barga, Toscana
·
Since 2001
Kedrion Biopharma, headquartered in Barga, Tuscany, Italy, is a biopharmaceutical company founded in 2001 that collects and processes human plasma to produce therapies for rare and ultra-rare diseases. The privately held firm employs 5,000–10,000 people and generates €1.5 billion in annual revenue. It operates a vertically integrated model spanning plasma collection, manufacturing, and distribution across over 100 countries, ranking as player in the plasma-derived sector with a portfolio of 38 products targeting hemophilia, neurological disorders, and immunodeficiencies.
Kedrion Biopharma at a glance
Revenue
$1-5B
Est. band
Employees
5,000-10,000
Founded
2001
Headquarters
Barga, Toscana
Certifications
ISO 45001
Import activity
5
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
5
Named foreign suppliers
5
Top origins
Italy · Belgium

Shared foreign counterparties do not establish that these companies buy from Kedrion Biopharma.
What this tells a buyer
Kedrion announced in May 2026 a €150 million investment to triple its production capacity, expanding operations in Italy's plasma-focused region.
The company manufactures plasma-derived therapies including immunoglobulins and coagulation factors, and holds ISO 45001 certification for occupational health and safety management.
Kedrion operates more than 70 plasma collection centers globally and manages supply chains from Switzerland and Italy, with recent product launches including YIMMUGO through distribution partnerships in the United States.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
25 years in operation (founded 2001).
5 US import shipments on record.
Holds ISO 45001 certification(s) per public sources.
Overview
Kedrion Biopharma, headquartered in Barga, Tuscany, Italy, is a biopharmaceutical company founded in 2001 that collects and processes human plasma to produce therapies for rare and ultra-rare diseases. The privately held firm employs 5,000–10,000 people and generates €1.5 billion in annual revenue. It operates a vertically integrated model spanning plasma collection, manufacturing, and distribution across over 100 countries, ranking as player in the plasma-derived sector with a portfolio of 38 products targeting hemophilia, neurological disorders, and immunodeficiencies.
At a glance
Attribute | Detail |
|---|---|
Founded | 2001 |
Headquarters | Barga, Toscana |
Employees | 5,000-10,000 |
Revenue | $1-5B (estimated) |
Certifications | ISO 45001 |
What Kedrion Biopharma makes
The company manufactures plasma-derived therapies including immunoglobulins and coagulation factors, and holds ISO 45001 certification for occupational health and safety management.
Certifications
Kedrion Biopharma is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 45001 — kedrion.hu
Trade and customs footprint
Kedrion announced in May 2026 a €150 million investment to triple its production capacity, expanding operations in Italy's plasma-focused region. US customs bill-of-lading records list 5 inbound shipments across 5 foreign suppliers, with top origins including Italy · Belgium.
Latest developments
2026-08-18 — Kedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED® - Kedrion us (kedrion.us)
2026-05-11 — €150 million investment to triple Kedrion’s production capacity: Italy's “Plasma Valley” to treat rare diseases - Kedrion Biopharma (kedrion.com)
2026-04-20 — Kedrion delivers strong financial performance in 2025 - Kedrion Biopharma (kedrion.com)
2025-12-02 — AOM Expands Infusion Offerings with Yimmugo IVIG from Kedrion Biopharma (aominfusionrx.com)
2025-10-09 — Kedrion Biopharma and CuraScript SD Team Up to Launch YIMMUGO in the U.S. - Kedrion us (kedrion.us)
2025-09-29 — Kedrion Biopharma receives FDA approval for QIVIGY® and confirms its plan to increase investments in the US throughout its global operations - Kedrion Biopharma (kedrion.com)
Facilities
Kedrion Biopharma is headquartered in Barga, Toscana. Public sources also reference these locations:
Italy, Hungary — kedrion.com
Company details
Kedrion operates more than 70 plasma collection centers globally and manages supply chains from Switzerland and Italy, with recent product launches including YIMMUGO through distribution partnerships in the United States. Kedrion Biopharma was founded in 2001, has an estimated 5,000-10,000 employees, and is headquartered in Barga, Toscana. On the LightSource stability read it is rated "Established & active": 25 years in operation (founded 2001). 5 US import shipments on record. Holds ISO 45001 certification(s) per public sources.
Frequently asked questions
What does Kedrion Biopharma do?
Kedrion Biopharma, headquartered in Barga, Tuscany, Italy, is a biopharmaceutical company founded in 2001 that collects and processes human plasma to produce therapies for rare and ultra-rare diseases. The privately held firm employs 5,000–10,000 people and generates €1.5 billion in annual revenue. It operates a vertically integrated model spanning plasma collection, manufacturing, and distribution across over 100 countries, ranking as player in the plasma-derived sector with a portfolio of 38 products targeting hemophilia, neurological disorders, and immunodeficiencies.
Where is Kedrion Biopharma headquartered?
Kedrion Biopharma is headquartered in Barga, Toscana.
When was Kedrion Biopharma founded?
Kedrion Biopharma was founded in 2001.
How big is Kedrion Biopharma?
Kedrion Biopharma has an estimated 5,000-10,000 employees, with revenue in the $1-5B range (estimated).
What certifications does Kedrion Biopharma hold?
Kedrion Biopharma lists ISO 45001 on its website. Confirm the certified scope for the specific plant producing your part.
Does Kedrion Biopharma import from overseas suppliers?
US customs bill-of-lading records show 5 inbound shipments for Kedrion Biopharma, with top origins including Italy · Belgium.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
